Pacific Biosciences of California Inc [NASDAQ: PACB] stock went on an upward path that rose over 0.74% on Friday, amounting to a one-week price decrease of less than -6.80%.
Over the last 12 months, PACB stock dropped by -89.46%. The one-year Pacific Biosciences of California Inc stock forecast points to a potential upside of 58.86. The average equity rating for PACB stock is currently 2.13, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $373.13 million, with 267.74 million shares outstanding and 264.11 million shares in the current float. Compared to the average trading volume of 10.50M shares, PACB stock reached a trading volume of 21104603 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pacific Biosciences of California Inc [PACB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $3.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.13. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Pacific Biosciences of California Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 03, 2024. The new note on the price target was released on April 22, 2024, representing the official price target for Pacific Biosciences of California Inc stock. Previously, the target price had yet another drop from $7 to $2.50, while Goldman kept a Neutral rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc is set at 0.17, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 1.86. The Price to Book ratio for the last quarter was 0.57, with the Price to Cash per share for the same quarter was set at 2.06.
PACB Stock Performance Analysis:
Pacific Biosciences of California Inc [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.80. With this latest performance, PACB shares dropped by -24.73% in over the last four-week period, additionally sinking by -86.42% over the last 6 months – not to mention a drop of -89.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 32.35, with the RSI for the last a single of trading hit 26.40, and the three-weeks RSI is set at 34.84 for Pacific Biosciences of California Inc [PACB]. The present Moving Average for the last 50 days of trading for this stock 1.7504, while it was recorded at 1.3870 for the last single week of trading, and 5.6048 for the last 200 days.
Insight into Pacific Biosciences of California Inc Fundamentals:
Pacific Biosciences of California Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.36 and a Current Ratio set at 9.28.
PACB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc go to -1.00%.
Pacific Biosciences of California Inc [PACB] Institutonal Ownership Details
The top three institutional holders of PACB stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in PACB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in PACB stock with ownership which is approximately 5.8386%.
